Patents by Inventor Bakulesh Mafatlal Khamar
Bakulesh Mafatlal Khamar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130295648Abstract: The present invention relates to increase in survival of mammals suffering from desmocollin 3 expressing cancers. Mycobacterium w is administered to mammals suffering from desmocollin-3 expressing cancers. The administration of Mycobacterium w results in control of tumor and improvement in survival. Mycobacterium w can also be used along with other therapeutic agent(s)/modalities as per the requirement. The squamous type of non small cell lung cancer is known to be desmocollin-3 expressing cancer. Other cancers also express desmocollin-3.Type: ApplicationFiled: January 10, 2012Publication date: November 7, 2013Inventors: Bakulesh Mafatlal Khamar, Indravadan Ambalal Modi
-
Patent number: 8563517Abstract: The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. wherein, A is defined as R3-R4 wherein R3 and R4 are together or independently defined as peptides having amino acids ranging from 1 to 10, B is chemical bond between peptide and substituted amine, R1, and R2 are as defined in specification.Type: GrantFiled: September 11, 2009Date of Patent: October 22, 2013Assignee: Cadila Pharmaceuticals LimitedInventors: Bakulesh Mafatlal Khamar, Singh Chandan, Rajiv Indravadan Modi
-
Publication number: 20130150578Abstract: The present invention relates to novel hypoglycemic compounds of formula (1) and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 1, 2011Publication date: June 13, 2013Applicant: CADILA PHARMACEUTICALS LIMITEDInventors: Bakulesh Mafatlal Khamar, Chandan Singh, Rajiv Indravadan Modi
-
Publication number: 20130137852Abstract: The present invention relates to process for preparation of novel compounds which are acting as inhibitors of dipeptidyl peptidase-IV enzyme and is depicted by the structural formula as given below: Formula VI. Which are useful in the treatment or prevention of diseases in which the dipeptidylpeptidase-IV enzyme is involved, such as diabetes and particularly type-2 diabetes.Type: ApplicationFiled: August 3, 2011Publication date: May 30, 2013Applicant: Cadila Corporate CampusInventors: Bakulesh Mafatlal Khamar, Nirav Kishorbhai Joshi, Chandan Hardhan Singh, Uday Rajaram Bapat, Bipin Dhanjibhai Gadhiya, Nirav Sureshbhai Sagar, Indravadan Ambalal Modi
-
Publication number: 20120328574Abstract: The invention relates to novel p38 MAPK inhibitor which involves Mycobacterium w and/or its constituents in pharmaceutically acceptable carriers and their uses. Mycobacterium w and/or its constituents when administered to mammal results in p38 inhibition The inhibition is found to last more than 28 days. It is also found to induce inhibition of TNF-? it suppresses cytokines in a pattern identical to Glucocorticoids. In transforms cells it also induces apoptosis. P38 mediated conditions include inflammation, cell differentiation, cell proliferation, cell inhibition, cell cycle regulation, anti-inflammatory reactions, immune modulation, vascularization, response to external stimuli and angiogenesis. The use of Mycobacterium w (Mw) and/or constituents of Mycobacterium w for inhibition of p38 protein kinase i.e. (i) to induce apoptosis in transformed cells (ii) for inhibition of TNF-? (iii) for inhibition of cytokines.Type: ApplicationFiled: June 28, 2012Publication date: December 27, 2012Applicant: Cadila Pharmaceuticals Ltd.Inventors: Indravadan Ambalal Modi, Prasanta Kumar Ghosh, Devesh Bhardwaj, Nirav Desai, Bakulesh Mafatlal Khamar
-
Patent number: 8333978Abstract: Mycobacterium w or its components are found to have poly TLR antagonistic activity to induced TLRs by varieties of TLR ligands. The induced TLR against which inhibitory effect is seen includes TLR 3, 4, 5, 6, 7, 8, 9. They also display antagonistic activities to effects of TLR ligands. They are also useful in management of diseases wherein TLRs are over expressed, like sepsis, multiple sclerosis, optic neuritis, Chronic obstructive pulmonary diseases multiple myeloma etc.Type: GrantFiled: November 21, 2007Date of Patent: December 18, 2012Assignee: Cadila PharmaceuticalsInventors: Indravadan Ambalal Modi, Bakulesh Mafatlal Khamar
-
Publication number: 20120308605Abstract: This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.Type: ApplicationFiled: February 17, 2011Publication date: December 6, 2012Applicant: Cadila Pharmaceuticals Ltd.Inventors: Bakulesh Mafatlal Khamar, Satinder Singh, Nirav Manojkumar Desai, Rajiv Indravadan Modi
-
Patent number: 8277778Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen(s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.Type: GrantFiled: September 23, 2011Date of Patent: October 2, 2012Assignee: Cadila Pharmaceuticals Ltd.Inventors: Bakulesh Mafatlal Khamar, Rajiv Indravadan Modi, Indravadan Ambalal Modi, Prasanta Kumar Ghosh, Nirav Desai
-
Patent number: 8153102Abstract: The invention relates to process for the preparation of formulations comprising a microorganism Mycobacterium w for the management of bronchial Asthma (obstructive lung disease).Type: GrantFiled: March 11, 2003Date of Patent: April 10, 2012Assignee: Cadila Pharmaceuticals Ltd.Inventors: Rajiv Indravadan Modi, Bakulesh Mafatlal Khamar
-
Patent number: 8110204Abstract: Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs. These drugs have their own side effects and immune reconstitution achieved is delayed and slow. Various attempts have been made to improve CD4 count, use of IL-2 is one of them. It is associated with systemic side effects during the period of its administration. The present invention provides method of using mycobacterium w for the management of HIV. According to present invention mycobacterium w when given intradermally is effective in prophylaxis and treatment of AIDS or AIDS related complex (ARC). It is found to improve immunity as well as CD4 count. It is found to eliminate symptoms like fever, diarrhea.Type: GrantFiled: January 17, 2002Date of Patent: February 7, 2012Assignee: Cadila Pharmaceuticals Ltd.Inventors: Bakulesh Mafatlal Khamar, Indravadan Ambalal Modi
-
Publication number: 20120027849Abstract: The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from ?-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.Type: ApplicationFiled: February 8, 2010Publication date: February 2, 2012Applicant: CADILA PHARMACEUTICALS LIMITEDInventors: Bakulesh Mafatlal Khamar, Kumud Kumar Padhee, Nilamkumari Somalal Patel, Sunil Chowdary Koduri, Amit Mukharya, Indravadan Ambalal Modi, Rajiv Indravadan Modi
-
Publication number: 20120014985Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: CADILA PHARMACEUTICALS LTD.Inventors: BAKULESH MAFATLAL KHAMAR, Rajiv Indravadan Modi, Indravadan Ambalal Modi, Prasanta Kumar Ghosh, Nirav Desai
-
Patent number: 8048434Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.Type: GrantFiled: April 21, 2006Date of Patent: November 1, 2011Assignee: Cadila Pharmaceuticals, Ltd.Inventors: Bakulesh Mafatlal Khamar, Rajiv Indravadan Modi, Indravadan Ambalal Modi, Prasanta Kumar Ghosh, Nirav Desai
-
Publication number: 20110182939Abstract: The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response.Type: ApplicationFiled: September 26, 2009Publication date: July 28, 2011Applicant: CADILA PHARMACEUTICALS LTD.Inventors: Bakulesh Mafatlal Khamar, Ambalal Indravadan Modi, Indravadan Rajiv Modi
-
Publication number: 20110183919Abstract: The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme.Type: ApplicationFiled: September 11, 2009Publication date: July 28, 2011Applicant: CADILA PHARMACEUTICALS LTD.Inventors: Bakulesh Mafatlal Khamar, Singh Chandan, Rajiv Indravadan Modi
-
Patent number: 7972609Abstract: Present invention relates to the method of treating cancer. According to present invention, a pharmaceutical composition made from ‘Mycobacterium w’ (Mw) is found to be useful in the management of cancer. We have now found that the same therapeutic agent is useful in management of cancer. The use of Mycobacterium w containing formulations is associated with decrease in burden of cancer tissue, decreasing symptoms associated with cancer and improving quality of life. It also improves tolerance to other therapies.Type: GrantFiled: December 10, 2002Date of Patent: July 5, 2011Assignee: Cadila Pharmaceuticals Ltd.Inventor: Bakulesh Mafatlal Khamar
-
Publication number: 20110020440Abstract: The present invention relates to a stable pharmaceutical composition comprising soft gelatin capsules containing at least one sparingly soluble active drug (singly or in combination with sparingly soluble and/or soluble drugs) and a solvent system, wherein the solvent system comprises of solvent, co-solvent, solubilizer(s), surfactant, aqueous solution of alkali and crystal growth inhibitor. The present invention further relates to process for preparing a stable pharmaceutical composition of sparingly soluble active drug(s) in soft gelatin capsules.Type: ApplicationFiled: November 15, 2008Publication date: January 27, 2011Applicant: CADILA PHARMACEUTICALS LIMITEDInventors: Indravadan Ambalal Modi, Bakulesh Mafatlal Khamar, Ashok Sitaram Omray, Vandana Patravale, Kartik Yogesh Shah, Prashant Yogesh Patel
-
Publication number: 20100209394Abstract: The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions.Type: ApplicationFiled: June 26, 2008Publication date: August 19, 2010Applicant: CADILA PHARMACEUTICALS LTD.Inventors: Rajiv Indravadan Modi, Devesh Bhardwaj, Nirav M. Desai, Bakulesh Mafatlal Khamar
-
Publication number: 20100113802Abstract: The invention relates to the HMG-CoA reductase inhibitor in particular to Atorvastatin Hemi-calcium. The present invention is directed to novel processes for preparing amorphous form of Atorvastatin hemi calcium and their intermediate in high purity.Type: ApplicationFiled: October 29, 2007Publication date: May 6, 2010Applicant: Cadila Pharmaceuticals LimitedInventors: Indravadan Ambalal Modi, Pratima Jain, Amarsingh L. Rajput, Prabhakar Motiram Tekade, Atul Chhotalal Joshi, Ravi Ponnaiah, Bakulesh Mafatlal Khamar
-
Publication number: 20100104536Abstract: The invention relates to novel p38 MAPK inhibitor which involves Mycobacterium w and/or its constituents in pharmaceutically acceptable carriers and their uses. Mycobacterium w and/or its constituents when administered to mammal results in p38 inhibition The inhibition is found to last more than 28 days. It is also found to induce inhibition of TNF-alfa. it suppresses cytokines in a pattern identical to Glucocorticoids. In transforms cells it also induces apoptosis. P38 mediated conditions include inflammation, cell differentiation, cell proliferation, cell inhibition, cell cycle regulation, anti-inflammatory reactions, immune modulation, vascularization, response to external stimuli and angiogenesis. The use of Mycobacterium w (Mw) and/or constituents of Mycobacterium w for inhibition of p38 protein kinase i.e. (i) to induce apoptosis in transformed cells (ii) for inhibition of TNF-alfa (iii) for inhibition of cytokines.Type: ApplicationFiled: March 18, 2008Publication date: April 29, 2010Inventors: Indravadan Ambalal Modi, Prasanta Kumar Ghosh, Devesh Bhardwaj, Nirav Desai, Bakulesh Mafatlal Khamar